• Genetic TherapyEnrolling

  Study of ARCT-032 in adults with cystic fibrosis who are not on CFTR modulator therapy. , protocol number Arcturus ARCT-032-02 Cohort 4

  This study will test the safety, tolerability and effectiveness of ARCT-032, a nebulized therapy intended to deliver a new, correct copy of CFTR messenger RNA (mRNA) to cells.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    45 to 90%

  • Number of Visits:

    13

  • Length of Participation:

    24 weeks

• Restore CFTR ProteinEnrolling

  Study of VX-828 in combination with Tezacaftor and Deutivacaftor in healthy participants and in adults with cystic fibrosis. , protocol number Vertex VX23-828-001 Phase 1 Part E

  Part E of this study will look at the safety and tolerability of VX-828 in combination with Tezacaftor and Deutivacaftor in adults with CF. The drug combination is intended to help CFTR function closer to normal. 

  • Age:

    18 Years and Older

  • Mutation(s):

    One Copy F508del

  • FEV1% Predicted:

    40% or greater

  • Number of Visits:

    12

  • Length of Participation:

    4 months

• Anti-InflammatoryEnrolling

  Study to evaluate BI 1291583 in adults with bronchiectasis , protocol number BI 1397-0014 (Airtivity)

  This study will test the effectiveness, safety, and tolerability of BI 1291583, a drug intended to reduce inflammation in the lungs.

  • Age:

    12 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    50 to 100%

  • Number of Visits:

    9

  • Length of Participation:

    76 weeks

• Anti-InfectiveEnrolling

  ABATE: Study to evaluate IV gallium in adults with cystic fibrosis who have nontuberculous mycobacteria (NTM) , protocol number ABATE-IP-18

  This study is taking place at multiple care centers across the U.S. It will look at the safety and tolerability of IV gallium, a drug intended to treat infections in the lung.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    25% or greater

  • Number of Visits:

    8

  • Length of Participation:

    20 weeks

• Nutritional-GIEnrolling

  Study to evaluate ANG003 in people with CF ages 12 and older , protocol number Anagram ANG003-25-201

  This study will assess the safety and effectiveness of ANG003, a pancreatic enzyme replacement therapy, also known as “enzymes” or “enzyme therapy”, to see whether it works as well as the approved enzyme therapy Creon.

  • Age:

    12 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    30% or greater

  • Number of Visits:

    6

  • Length of Participation:

    3 months

• ObservationalEnrolling

  PREDICT: NTM observational study , protocol number NTM-OB-17 (PREDICT)

  This study is taking place at multiple care centers across the U.S. It will evaluate the current standard of diagnosing nontuberculous mycobacteria (NTM) in people with CF.

  • Age:

    6 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    20

  • Length of Participation:

    5 years

• OtherEnrolling

  A study to evaluate the insulin-only Bionic Pancreas in people with cystic fibrosis 14 years of age or older who have cystic fibrosis-related diabetes (CFRD) , protocol number Bionic Pancreas CFRD IOBP V 1.0.

  This study will evaluate the effectiveness and safety of using the insulin-only Bionic Pancreas (BP) system compared to using one’s usual insulin delivery method.

  • Age:

    14 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    4

  • Length of Participation:

    7 months

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.